ORMP Oramed Pharmaceuticals Inc.

4.58
-0.09  -2%
Previous Close 4.67
Open 4.65
Price To Book 4.13
Market Cap 79,683,353
Shares 17,398,112
Volume 114,859
Short Ratio
Av. Daily Volume 177,282
Stock charts supplied by TradingView

NewsSee all news

  1. Oramed Appoints Dr. Arie Mayer to Board of Directors

    NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  2. Oramed to Present a Scientific Poster at International Diabetes Federation Congress

    NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  3. Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

    NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced

  4. Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted

  5. Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data noted 2/3 arms showed significant reductions. Data from second cohort due 1Q 2020.
ORMD-0801
Type 2 Diabetes
Phase 1 trial completed. Assessing options for future development.
ORMD-0901
Type 2 diabetes
Phase 2 first cohort to be completed 4Q 2019.
ORMD-0801
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Oramed Appoints Dr. Arie Mayer to Board of Directors

    NEW YORK, Dec. 5, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

  2. Oramed to Present a Scientific Poster at International Diabetes Federation Congress

    NEW YORK, December 2, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  3. Oramed Patent Granted in Japan for Protease Inhibitor, a Key Component of Platform Technology

    NEW YORK, Nov. 21, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced

  4. Oramed Provides Highlights and Data From Its Phase IIb Oral Insulin Study Investor Event

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, conducted

  5. Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

    NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor

  6. Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

    NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced

  7. Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  8. Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

    NEW YORK, Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the

  9. Oramed to Present at Three Upcoming Conferences

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today